{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:16:26Z","timestamp":1791062186487,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11255-019-02271-6","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T04:07:56Z","timestamp":1568693276000},"page":"2027-2036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"51","author":[{"given":"Jun","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"issue":"2","key":"2271_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","volume":"139","author":"AS Levey","year":"2003","unstructured":"Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139(2):137\u2013147","journal-title":"Ann Intern Med"},{"issue":"6","key":"2271_CR2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1053\/j.ajkd.2013.08.011","volume":"63","author":"M Fukagawa","year":"2014","unstructured":"Fukagawa M, Kido R, Komaba H, Onishi Y, Yamaguchi T, Hasegawa T, Kurita N, Fukuma S, Akizawa T, Fukuhara S (2014) Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Am J Kidney Dis 63(6):979\u2013987","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2271_CR3","doi-asserted-by":"publisher","first-page":"e001363","DOI":"10.1161\/JAHA.114.001363","volume":"3","author":"DC Wheeler","year":"2014","unstructured":"Wheeler DC, London GM, Parfrey PS, Block GA, Correa-Rotter R, Dehmel B, Drueke TB, Floege J, Kubo Y, Mahaffey KW et al (2014) Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. J Am Heart Assoc 3(6):e001363","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"2271_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00198-012-1993-y","volume":"24","author":"DK Dhanwal","year":"2013","unstructured":"Dhanwal DK, Sahoo S, Gautam VK, Saha R (2013) Hip fracture patients in India have vitamin D deficiency and secondary hyperparathyroidism. Osteoporos Int 24(2):553\u2013557","journal-title":"Osteoporos Int"},{"issue":"6","key":"2271_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1159\/000369939","volume":"40","author":"SM Sprague","year":"2014","unstructured":"Sprague SM, Silva AL, Al-Saghir F, Damle R, Tabash SP, Petkovich M, Messner EJ, White JA, Melnick JZ, Bishop CW (2014) Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol 40(6):535\u2013545","journal-title":"Am J Nephrol"},{"issue":"11","key":"2271_CR6","doi-asserted-by":"publisher","first-page":"E708","DOI":"10.3390\/nu8110708","volume":"8","author":"JQ Zheng","year":"2016","unstructured":"Zheng JQ, Hou YC, Zheng CM, Lu CL, Liu WC, Wu CC, Huang MT, Lin YF, Lu KC (2016) Cholecalciferol additively reduces serum parathyroid hormone and increases vitamin D and cathelicidin levels in paricalcitol-treated secondary hyperparathyroid hemodialysis patients. Nutrients 8(11):E708","journal-title":"Nutrients"},{"issue":"1","key":"2271_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000452680","volume":"45","author":"R Thadhani","year":"2017","unstructured":"Thadhani R, Zella JB, Knutson DC, Blaser WJ, Plum LA, Clagett-Dame M, Buck RD, DeLuca HF (2017) 2MD (DP001), a single agent in the management of hemodialysis patients: a randomized trial. Am J Nephrol 45(1):40\u201348","journal-title":"Am J Nephrol"},{"issue":"6","key":"2271_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2215\/CJN.07050714","volume":"10","author":"JB Wetmore","year":"2015","unstructured":"Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K (2015) A randomized trial of cinacalcet versus vitamin d analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol 10(6):1031\u20131040","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2271_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000350211","volume":"37","author":"K Sumida","year":"2013","unstructured":"Sumida K, Nakamura M, Ubara Y, Marui Y, Tanaka K, Takaichi K, Tomikawa S, Inoshita N, Ohashi K (2013) Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients. Am J Nephrol 37(5):405\u2013412","journal-title":"Am J Nephrol"},{"key":"2271_CR10","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1038\/s41598-018-21397-8","volume":"8","author":"GQ Wang","year":"2018","unstructured":"Wang GQ, Liu HY, Wang CZ, Ji XJ, Gu WJ, Mu YM (2018) Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis. Sci Rep 8:3111","journal-title":"Sci Rep"},{"key":"2271_CR11","volume-title":"Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database of Systematic Reviews","author":"E Ballinger Angela","year":"2014","unstructured":"Ballinger Angela E, Palmer Suetonia C, Nistor I, Craig Jonathan C, Strippoli Giovanni FM (2014) Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database of Systematic Reviews. Wiley, New York"},{"issue":"10","key":"2271_CR12","doi-asserted-by":"publisher","first-page":"e48070","DOI":"10.1371\/journal.pone.0048070","volume":"7","author":"Q Zhang","year":"2012","unstructured":"Zhang Q, Li M, You L, Li H, Ni L, Gu Y, Hao C, Chen J (2012) Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis. PLoS One 7(10):e48070","journal-title":"PLoS One"},{"key":"2271_CR13","doi-asserted-by":"crossref","unstructured":"Greeviroj P, Kitrungphaiboon T, Katavetin P, Praditpornsilpa K, Eiam-Ong S, Jaber B, Susantitaphong P (2018) Cinacalcet for treatment of chronic kidney disease-mineral and bone disorder: a meta-analysis of randomized controlled trials. Nephron 139(3):197\u2013210","DOI":"10.1159\/000487546"},{"issue":"6","key":"2271_CR14","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3109\/0886022X.2016.1172468","volume":"38","author":"N Sekercioglu","year":"2016","unstructured":"Sekercioglu N, Busse J, Sekercioglu M, Agarwal A, Shaikh S, Lopes L, Mustafa R, Guyatt G, Thabane L (2016) Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis. Ren Fail 38(6):857\u2013874","journal-title":"Ren Fail"},{"issue":"7","key":"2271_CR15","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097","journal-title":"PLoS Med"},{"issue":"3","key":"2271_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/jrsm.1102","volume":"5","author":"C Robertson","year":"2014","unstructured":"Robertson C, Ramsay C, Gurung T, Mowatt G, Pickard R, Sharma P (2014) Practicalities of using a modified version of the Cochrane Collaboration risk of bias tool for randomised and non-randomised study designs applied in a health technology assessment setting. Res Synth Methods 5(3):200\u2013211","journal-title":"Res Synth Methods"},{"key":"2271_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135","journal-title":"BMC Med Res Methodol"},{"issue":"7414","key":"2271_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed) 327(7414):557\u2013560","journal-title":"BMJ (Clin Res Ed)"},{"issue":"4","key":"2271_CR19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/jrsm.53","volume":"2","author":"K Thorlund","year":"2011","unstructured":"Thorlund K, Wetterslev J, Awad T, Thabane L, Gluud C (2011) Comparison of statistical inferences from the DerSimonian\u2013Laird and alternative random-effects model meta-analyses\u2014an empirical assessment of 920 Cochrane primary outcome meta-analyses. Res Synth Methods 2(4):238\u2013253","journal-title":"Res Synth Methods"},{"issue":"6","key":"2271_CR20","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2215\/CJN.01040308","volume":"3","author":"S Fishbane","year":"2008","unstructured":"Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, Ling X, Goodman WG, Turner S, Charytan C (2008) Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 3(6):1718\u20131725","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2271_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2215\/CJN.03630509","volume":"5","author":"JB Wetmore","year":"2010","unstructured":"Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD (2010) Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 5(1):110\u2013116","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2271_CR22","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G et al (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26(4):1327\u20131339","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2271_CR23","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1093\/ndt\/gfr531","volume":"27","author":"M Ketteler","year":"2012","unstructured":"Ketteler M, Martin KJ, Cozzolino M, Goldsmith D, Sharma A, Khan S, Dumas E, Amdahl M, Marx S, Audhya P (2012) Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrol Dial Transplant 27(5):1942\u20131949","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2271_CR24","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1210\/jc.2012-3246","volume":"98","author":"M Rodriguez","year":"2013","unstructured":"Rodriguez M, Urena-Torres P, Petavy F, Cooper K, Farouk M, Goodman WG (2013) Calcium-mediated parathyroid hormone suppression to assess progression of secondary hyperparathyroidism during treatment among incident dialysis patients. J Clin Endocrinol Metab 98(2):618\u2013625","journal-title":"J Clin Endocrinol Metab"},{"key":"2271_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1471-2369-14-112","volume":"14","author":"HJ Kim","year":"2013","unstructured":"Kim HJ, Kim H, Shin N, Na KY, Kim YL, Kim D, Chang JH, Song YR, Hwang YH, Kim YS et al (2013) Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study. BMC Nephrol 14:112","journal-title":"BMC Nephrol"},{"issue":"5","key":"2271_CR26","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/ndt\/gfs568","volume":"28","author":"P Urena-Torres","year":"2013","unstructured":"Urena-Torres P, Bridges I, Christiano C, Cournoyer SH, Cooper K, Farouk M, Kopyt NP, Rodriguez M, Zehnder D, Covic A (2013) Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transplant 28(5):1241\u20131254","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2271_CR27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/ndt\/gfu011","volume":"29","author":"M Cozzolino","year":"2014","unstructured":"Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S (2014) Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Nephrol Dial Transplant 29(4):899\u2013905","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2271_CR28","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/nu5041336","volume":"5","author":"YT Lee","year":"2013","unstructured":"Lee YT, Ng HY, Kuo CC, Chen TC, Wu CS, Chiu TT, Lee WC, Lee CT (2013) Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients. Nutrients 5(4):1336\u20131348","journal-title":"Nutrients"},{"issue":"2","key":"2271_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1542-4758.2011.00642.x","volume":"16","author":"GM Chertow","year":"2012","unstructured":"Chertow GM, Lu ZJ, Xu X, Knight TG, Goodman WG, Bushinsky DA, Block GA (2012) Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodial Int Symp Home Hemodial 16(2):188\u2013197","journal-title":"Hemodial Int Symp Home Hemodial"},{"issue":"2","key":"2271_CR30","doi-asserted-by":"publisher","first-page":"E196","DOI":"10.3390\/nu10020196","volume":"10","author":"CM Zheng","year":"2018","unstructured":"Zheng CM, Wu CC (2018) Cholecalciferol additively reduces serum parathyroid hormone levels in severe secondary hyperparathyroidism treated with calcitriol and cinacalcet among hemodialysis patients. Nutrients 10(2):E196","journal-title":"Nutrients"},{"issue":"1","key":"2271_CR31","first-page":"531","volume":"17","author":"H Ye","year":"2019","unstructured":"Ye H, Ye P, Zhang Z, Hou A, Liang Z, Kong Y (2019) A Bayesian network analysis on comparative efficacy of treatment strategies for dialysis patients with secondary hyperparathyroidism. Exp Ther Med 17(1):531\u2013540","journal-title":"Exp Ther Med"},{"issue":"10","key":"2271_CR32","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1097\/TP.0b013e31826c3968","volume":"94","author":"JB Cohen","year":"2012","unstructured":"Cohen JB, Gordon CE, Balk EM, Francis JM (2012) Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis. Transplantation 94(10):1041\u20131048","journal-title":"Transplantation"},{"issue":"4","key":"2271_CR33","doi-asserted-by":"publisher","first-page":"F1215","DOI":"10.1152\/ajprenal.00406.2006","volume":"292","author":"G Rashid","year":"2007","unstructured":"Rashid G, Bernheim J, Green J, Benchetrit S (2007) Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Ren Physiol 292(4):F1215\u2013F1218","journal-title":"Am J Physiol Ren Physiol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02271-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02271-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02271-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T23:10:08Z","timestamp":1600211408000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02271-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2271"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02271-6","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"8 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}